Functional Class News Today

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,...

Cytokinetics, Incorporated announced additional 48-week data from FOREST-HCM , the open label extension clinical study of aficamten in patients with hypertrophic cardiomyopathy , at the 73rd Annual...

Sotatercept with background therapy significantly improved exercise capacity and multiple secondary outcome measures compared to background therapy alone in the STELLAR trial.

Preparing to launch YUTREPIA™ inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent...

MORRISVILLE, N.C., Jan. 25, 2024 -- Liquidia Corporation announced today that the U.S. Food and Drug Administration provided an update on its review of the New Drug Application for YUTREPIA™ ...

Liquidia Corporation Announces Updates to Operations Leadership

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is...

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests...

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is invalid and is

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,...